Disease Detail

ID DOID:2531
Name hematologic cancer
Definition An organ system cancer located in the hematological system that is characterized by uncontrolled cellular proliferation in blood, bone marrow and lymph nodes.
Source DiseaseOntology.org
Alt Ids DOID:2532 DOID:1034
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Idelalisib hematologic cancer not applicable detail...
PIK3CA mutant CUDC-907 hematologic cancer sensitive detail...
JAK2 V617F JAK2 E864K NVP-BSK805 hematologic cancer resistant detail...
JAK2 V617F JAK2 E864K NVP-BVB808 hematologic cancer resistant detail...
JAK2 V617F JAK2 E985K Ruxolitinib hematologic cancer resistant detail...
JAK2 V617F JAK2 G935R Ruxolitinib hematologic cancer resistant detail...
JAK2 V617F JAK2 G935R NVP-BSK805 hematologic cancer resistant detail...
JAK2 V617F JAK2 G935R NVP-BVB808 hematologic cancer resistant detail...
JAK2 V617F JAK2 I960V Ruxolitinib hematologic cancer resistant detail...
JAK2 V617F JAK2 I960V Lestaurtinib hematologic cancer resistant detail...
JAK2 V617F JAK2 I960V SAR302503 hematologic cancer resistant detail...
JAK2 V617F JAK2 I960V AZD1480 hematologic cancer resistant detail...
JAK2 V617F JAK2 I960V Momelotinib hematologic cancer resistant detail...
JAK2 V617F JAK2 M929I Ruxolitinib hematologic cancer resistant detail...
JAK2 V617F JAK2 R938L Ruxolitinib hematologic cancer resistant detail...
JAK2 V617F JAK2 R938L Momelotinib hematologic cancer resistant detail...
JAK2 V617F JAK2 R938L Lestaurtinib hematologic cancer resistant detail...
JAK2 V617F JAK2 R938L SAR302503 hematologic cancer resistant detail...
JAK2 V617F JAK2 R938L AZD1480 hematologic cancer resistant detail...
ETV6-JAK2 JAK2 R975G Pyridone 6 hematologic cancer resistant detail...
ETV6-JAK2 JAK2 V881A Pyridone 6 hematologic cancer resistant detail...
ETV6-JAK2 JAK2 N909K Pyridone 6 hematologic cancer resistant detail...
FBXW7 inact mut Belinostat hematologic cancer sensitive detail...
FBXW7 inact mut AR-42 hematologic cancer sensitive detail...
KIT D816V Sorafenib hematologic cancer resistant detail...
KIT D816V Imatinib hematologic cancer resistant detail...
IDH2 mutant Enasidenib hematologic cancer sensitive detail...
Unknown unknown Umbralisib hematologic cancer not applicable detail...
FBXW7 inact mut Entinostat hematologic cancer sensitive detail...
PTPN11 E76K II-B08 hematologic cancer sensitive detail...
Unknown unknown CUDC-907 hematologic cancer not applicable detail...
Unknown unknown SNX-7081 hematologic cancer not applicable detail...
Unknown unknown GS-9820 hematologic cancer not applicable detail...
Unknown unknown RP6530 hematologic cancer not applicable detail...
Unknown unknown OPB-51602 hematologic cancer no benefit detail...
ETV6 - JAK2 JAK2 E864K Pyridone 6 hematologic cancer resistant detail...
ETV6 - JAK2 JAK2 G831R Pyridone 6 hematologic cancer resistant detail...
ETV6 - JAK2 JAK2 G935R Pyridone 6 hematologic cancer resistant detail...
ETV6 - JAK2 JAK2 M929I Pyridone 6 hematologic cancer resistant detail...
ETV6 - JAK2 JAK2 P1057S Pyridone 6 hematologic cancer resistant detail...
ETV6 - JAK2 JAK2 R1127K Pyridone 6 hematologic cancer resistant detail...
ETV6 - JAK2 JAK2 Y918H Pyridone 6 hematologic cancer resistant detail...
JAK2 R867Q SAR302503 hematologic cancer decreased response detail...
JAK2 R867Q Ruxolitinib hematologic cancer decreased response detail...
JAK2 R867Q AZ960 hematologic cancer decreased response detail...
JAK2 R867Q Momelotinib hematologic cancer decreased response detail...
JAK2 R867Q Luminespib hematologic cancer decreased response detail...
MPL W515L CHZ868 hematologic cancer sensitive detail...
JAK2 V617F SHP099 hematologic cancer sensitive detail...
NRAS mutant SHP099 hematologic cancer predicted - resistant detail...
Unknown unknown APR-246 hematologic cancer not applicable detail...
Unknown unknown ID09C3 hematologic cancer not applicable detail...
Unknown unknown Tefinostat hematologic cancer not applicable detail...
SF3B1 K700E E7107 hematologic cancer sensitive detail...
Unknown unknown ABT-348 hematologic cancer not applicable detail...
Unknown unknown TTI-621 hematologic cancer not applicable detail...
Unknown unknown Abexinostat hematologic cancer not applicable detail...
Unknown unknown Cenisertib hematologic cancer not applicable detail...
Unknown unknown GSK1070916 hematologic cancer not applicable detail...
Unknown unknown M7583 hematologic cancer not applicable detail...
Unknown unknown TAS4464 hematologic cancer not applicable detail...
Unknown unknown Fenretinide hematologic cancer not applicable detail...
BRAF K601N LY3009120 hematologic cancer sensitive detail...
Unknown unknown AZD5991 hematologic cancer not applicable detail...
Unknown unknown Glasdegib hematologic cancer not applicable detail...
JAK2 V617F NS-018 hematologic cancer sensitive detail...
MPL W515L NS-018 hematologic cancer sensitive detail...
ETV6-JAK2 NS-018 hematologic cancer sensitive detail...
ETV6-JAK3 NS-018 hematologic cancer predicted - resistant detail...
FLT3 exon 14 ins FLT3 N676D G-749 hematologic cancer sensitive detail...
FLT3 exon 14 ins FLT3 F691L G-749 hematologic cancer sensitive detail...
FLT3 D835Y G-749 hematologic cancer sensitive detail...
FLT3 D835Y FLT3 N676D G-749 hematologic cancer sensitive detail...
FLT3 exon 14 ins GTP-14564 hematologic cancer sensitive detail...
JAK2 V617F BMS-911543 hematologic cancer sensitive detail...
MPL W515L BMS-911543 hematologic cancer sensitive detail...
CALR L367fs Ruxolitinib hematologic cancer sensitive detail...
CALR K385fs Ruxolitinib hematologic cancer sensitive detail...
CALR L367fs Ruxolitinib + Temsirolimus hematologic cancer sensitive detail...
FGFR1 fusion Derazantinib hematologic cancer sensitive detail...
Unknown unknown BP1001 + Cytarabine hematologic cancer not applicable detail...
Unknown unknown BP1001 hematologic cancer not applicable detail...
KIT D816V FF-10101 hematologic cancer sensitive detail...
FLT3 exon 14 ins FLT3 Y842C FF-10101 hematologic cancer sensitive detail...
FLT3 exon 14 ins FLT3 Y842H FF-10101 hematologic cancer sensitive detail...
Unknown unknown AZD4573 hematologic cancer not applicable detail...
JAK3 A573V Tofacitinib hematologic cancer sensitive detail...
JAK3 M511I Tofacitinib hematologic cancer sensitive detail...
JAK3 H583Y Tofacitinib hematologic cancer sensitive detail...
JAK3 G589D Tofacitinib hematologic cancer sensitive detail...
Unknown unknown Milatuzumab hematologic cancer no benefit detail...
Unknown unknown CC-122 hematologic cancer not applicable detail...
Unknown unknown Domatinostat hematologic cancer not applicable detail...
FLT3 D835Y Crenolanib hematologic cancer sensitive detail...
FLT3 Y572C Crenolanib hematologic cancer sensitive detail...
FLT3 K429E Crenolanib hematologic cancer resistant detail...
FLT3 D835Y FLT3 F691L Crenolanib hematologic cancer resistant detail...
FLT3 D835Y FLT3 D200N Crenolanib hematologic cancer sensitive detail...
FLT3 D835Y FLT3 L601F Crenolanib hematologic cancer sensitive detail...
FLT3 D835Y Crenolanib + Trametinib hematologic cancer sensitive detail...
FLT3 D835Y PTPN11 A72D Crenolanib + Trametinib hematologic cancer sensitive detail...
FLT3 D835Y PTPN11 A72D Crenolanib hematologic cancer resistant detail...
FLT3 D835Y IDH1 wild-type AGI-5198 hematologic cancer resistant detail...
FLT3 D835Y IDH1 R132H AGI-5198 hematologic cancer resistant detail...
FLT3 D835Y IDH1 R132H Crenolanib hematologic cancer sensitive detail...
FLT3 D835Y IDH1 wild-type Crenolanib hematologic cancer sensitive detail...
FLT3 D835Y IDH1 R132H AGI-5198 + Crenolanib hematologic cancer sensitive detail...
FLT3 D835Y IDH1 wild-type AGI-5198 + Crenolanib hematologic cancer sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00074490 Phase II Cyclophosphamide Cyclosporine Rituximab Doxorubicin Etoposide Filgrastim Vincristine Fludarabine Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers Terminated
NCT00167180 Phase II Cyclophosphamide + Fludarabine Post Transplant Donor Lymphocyte Infusion Completed
NCT00305682 Phase II Sirolimus Mycophenolate mofetil anti-thymocyte globulin Cyclophosphamide Fludarabine Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant Active, not recruiting
NCT00520130 Phase Ib/II Cytarabine + Fludarabine Alemtuzumab + Cyclosporine Cyclophosphamide + Doxorubicin + Etoposide + Fludarabine + Prednisone + Rituximab + Vincristine Cyclophosphamide + Doxorubicin + Etoposide + Fludarabine + Prednisone + Vincristine Methotrexate + Sirolimus + Tacrolimus Filgrastim Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System Completed
NCT00697632 Phase I Glesatinib Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies Completed
NCT01203722 Phase Ib/II Tacrolimus Sirolimus Cyclophosphamide + Fludarabine + Mycophenolate mofetil Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies Recruiting
NCT01231412 Phase III Sirolimus Fludarabine Cyclosporine + Mycophenolate mofetil Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed
NCT01339871 Phase I Vorinostat Pazopanib Phase I Study of Pazopanib and Vorinostat Completed
NCT01375842 Phase I Atezolizumab A Phase 1 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors Completed
NCT01376310 Phase II Docetaxel + Trametinib Erlotinib + Trametinib Trametinib Pemetrexed + Trametinib Carboplatin + Trametinib Nab-paclitaxel + Trametinib Gemcitabine + Trametinib Everolimus + Trametinib GSK1120212 Rollover Study Terminated
NCT01529827 Phase II Melphalan Methotrexate Tacrolimus Mycophenolate mofetil Fludarabine Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Active, not recruiting
NCT01531894 Phase II Afuresertib Continuation Study of the Oral AKT Inhibitor GSK2110183 Completed
NCT01619761 Phase I Rituximab Fludarabine + Lenalidomide + Melphalan Mycophenolate mofetil Tacrolimus Natural Killer (NK) Cells in Cord Blood Transplantation Recruiting
NCT01635712 Phase I SNX-5422 Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies Completed
NCT01643603 Phase Ib/II Dasatinib Dasatinib in Treating Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant Active, not recruiting
NCT01664910 Phase Ib/II Bendamustine + Fludarabine + inotuzumab ozogamicin Rituximab anti-thymocyte globulin Tacrolimus CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies Recruiting
NCT01760655 Phase II Tacrolimus Cyclophosphamide + Fludarabine + Thiotepa Mycophenolate mofetil Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Recruiting
NCT01767766 Phase I Umbralisib Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies Active, not recruiting
NCT01822509 Phase I Ipilimumab + Nivolumab Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant Active, not recruiting
NCT01831726 Phase II Dovitinib Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Completed
NCT01833169 Phase II Buparlisib BKM120 for Patients With PI3K-activated Tumors Completed
NCT01885195 Phase II Binimetinib MEK162 for Patients With RAS/RAF/MEK Activated Tumors Completed
NCT01915498 Phase I Enasidenib Phase 1 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation Active, not recruiting
NCT01919619 Phase II Ipilimumab + Lenalidomide Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies Recruiting
NCT01954316 Phase I CFI-400945 A Study of CFI-400945 Fumarate in Patients With Advanced Cancer Recruiting
NCT01981187 Phase II Encorafenib LGX818 for Patients With BRAFV600 Mutated Tumors Completed
NCT02002689 Phase II Sonidegib LDE225 for Patients With PTCH1 or SMO Mutated Tumors Terminated
NCT02065869 Phase Ib/II BPX-501 Rimiducid Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant Active, not recruiting
NCT02074839 Phase I Ivosidenib Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation Active, not recruiting
NCT02076997 Phase I Methotrexate Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate Active, not recruiting
NCT02118311 Phase II Fludarabine Cyclophosphamide T Regulatory Cell for Suppression of Acute Graft-vs-Host-Disease After a Non-Myeloablative Umbilical Cord Blood Transplantation Withdrawn
NCT02160041 Phase II BGJ398 BGJ398 for Patients With Tumors With FGFR Genetic Alterations Terminated
NCT02162888 Phase I Bendamustine A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients Completed
NCT02186821 Phase II Ceritinib Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) Completed
NCT02187783 Phase II Ribociclib LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) Completed
NCT02223598 Phase I CB-5083 CB-5083 + Dexamethasone A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies (CLC-102) Terminated
NCT02272998 Phase II Ponatinib Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT. Recruiting
NCT02286687 Phase II Talazoparib Study of the PARP Inhibitor BMN 673 in Advanced Cancer Patients With Somatic Alterations in BRCA1/2, Mutations/Deletions in PTEN or PTEN Loss, a Homologous Recombination Defect, Mutations/Deletions in Other BRCA Pathway Genes and Germline Mutation in BRCA1/2 (Not Breast or Ovarian Cancer) Recruiting
NCT02333162 Phase I Mycophenolate mofetil Tacrolimus Fludarabine + Melphalan Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant Recruiting
NCT02343679 Phase II Ceritinib Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies Withdrawn
NCT02352558 Phase I Imatinib Napabucasin Bortezomib Ibrutinib Dexamethasone A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies Completed
NCT02362035 Phase Ib/II Acalabrutinib Pembrolizumab ACP-196 in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (KEYNOTE145) Active, not recruiting
NCT02369029 Phase I BAY 1238097 BAY1238097, First in Man Terminated
NCT02381886 Phase I IDH305 A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations Active, not recruiting
NCT02418000 Phase Ib/II E6201 A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation Terminated
NCT02419755 Phase II Cytarabine Mercaptopurine Methotrexate Pegaspargase Vorinostat Doxorubicin Bortezomib Dexamethasone Mitoxantrone Prednisone Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies Terminated
NCT02423915 Phase Ib/II Filgrastim Rituximab Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention Active, not recruiting
NCT02484053 Phase I Rituximab Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders Completed
NCT02492737 Phase I AG-881 Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation Completed
NCT02508038 Phase I Zoledronic acid Fludarabine + Melphalan Melphalan Tacrolimus anti-thymocyte globulin Mycophenolate mofetil Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa Recruiting
NCT02561988 Phase I Avapritinib Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies Recruiting
NCT02571036 Phase I DCC-2618 A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies Recruiting
NCT02576496 Phase I Tinostamustine Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies Active, not recruiting
NCT02584933 FDA approved Ceritinib Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study Recruiting
NCT02588105 Phase I Olaparib AZD0156 Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer Active, not recruiting
NCT02611063 Phase I Fostamatinib Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant Recruiting
NCT02612285 Phase II SNX-5422 Study of SNX-5422 in TP53 Null Cancers Terminated
NCT02639559 Phase II BKT140 Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies Active, not recruiting
NCT02658890 Phase Ib/II BMS-986205 + Ipilimumab + Nivolumab BMS-986205 + Nivolumab An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread Recruiting
NCT02663518 Phase I TTI-621 A Trial of TTI-621 for Patients With Hematologic Malignancies Recruiting
NCT02679131 Phase I Belinostat To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment. Terminated
NCT02680795 Phase I Belinostat To Evaluate the Safety and Pharmacokinetics of Belinostat in Patients Who Have Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes Recruiting
NCT02711137 Phase Ib/II INCB057643 A Phase 1/2, Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies Terminated
NCT02862275 Phase 0 Atezolizumab Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer Recruiting
NCT02889445 Expanded access DM-CHOC-PEN A Phase I Trial of DM-CHOC-PEN in Adolescent and Young Adult (AYA) Subjects With Advanced Cancers Temporarily not available
NCT02921919 Phase II Talazoparib Open-Label Extension and Safety Study of Talazoparib Recruiting
NCT02937675 Phase Ib/II Tomivosertib A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies Terminated
NCT02985554 Phase I Nivolumab Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies Recruiting
NCT03011372 Phase II Pemigatinib A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement Recruiting
NCT03075696 Phase I Obinutuzumab + RO7082859 + Tocilizumab A Dose Escalation Study of RO7082859, Administered After a Fixed, Single Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma Recruiting
NCT03151057 Phase I Idelalisib Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies Recruiting
NCT03219268 Phase I MGD013 A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms Recruiting
NCT03236857 Phase I Venetoclax A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies Recruiting
NCT03386513 Phase I IMGN632 Study of IMGN632 in Patients With Relapse/Refractory AML, BPDCN, ALL, Other CD123+ Hem Malignancies Recruiting
NCT03386526 Phase Ib/II APG-1387 APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies Recruiting
NCT03420430 Expanded access GL-ONC1 Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care Available
NCT03440437 Phase I FS118 FS118 First in Human Study in Patients With Advanced Malignancies After PD-1/PD-L1 Containing Therapy Recruiting
NCT03485547 Phase I Venetoclax Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Recruiting
NCT03512340 Phase I SRF231 Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers Recruiting
NCT03555955 Phase I CPX-351 A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 Recruiting
NCT03588936 Phase I Nivolumab + Tocilizumab Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant Recruiting
NCT03711604 Phase Ib/II RP6530 Compassionate Use Study of Tenalisib (RP6530) Recruiting
NCT03739606 Phase II Flotetuzumab Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Not yet recruiting
NCT03837899 Phase Ib/II Durvalumab + Tremelimumab Durvalumab Durvalumab and Tremelimumab for Pediatric Malignancies Recruiting
NCT03838926 Phase I Trichostatin A Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies Recruiting
NCT03850366 Phase II Bortezomib + Cyclophosphamide HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib Recruiting